Cardiol Therapeutics (CRDL) Operating Expenses (2020 - 2026)

Cardiol Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• Quarterly Operating Expenses rose 20.49% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (down 11.28% YoY) and the FY2025 annual result came in at $24.6 million, down 14.65% from the prior year.
• Operating Expenses was $7.1 million for Q1 2026 at Cardiol Therapeutics, up from $5.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $10.4 million in Q3 2024 and bottomed at $4.7 million in Q2 2023.
• A 5-year average of $6.8 million and a median of $6.2 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses slumped 43.66% — and 2024, when it surged 81.51%.
• Cardiol Therapeutics' Operating Expenses stood at $6.7 million in 2022, then declined by 11.98% to $5.9 million in 2023, then gained by 21.25% to $7.2 million in 2024, then declined by 19.47% to $5.8 million in 2025, then gained by 22.91% to $7.1 million in 2026.
• Business Quant data shows CRDL's Operating Expenses at $7.1 million in Q1 2026, $5.8 million in Q4 2025, and $7.4 million in Q3 2025.